JCR Pharma projects strong fiscal year 2026 growth, driven by gene therapy deals

JCR Pharmaceuticals reported robust consolidated financial results for the second quarter ended September 30, 2025, with revenue of JPY21,362 million, a 28.2% increase year-over-year, and operating profit of JPY2,379 million, a substantial turnaround from a JPY739 million loss in the prior year. This growth was primarily fueled by a significant rise in contract revenue, including a JPY4,999 million increase in contract gold. For the full fiscal year ending March 2026, the company forecasts revenue of JPY37,800 million (up 14.3%) and operating profit of JPY2,600 million.

Key strategic initiatives include licensing agreements for its innovative JUST-AAV gene therapy platform and J-Brain Cargo® technology. Alexion Pharmaceuticals signed a license agreement for up to five gene therapy programs, potentially yielding up to $825 million in milestone fees. Acumen Pharmaceuticals entered an option agreement for Alzheimer's disease treatments using J-Brain Cargo® technology, with potential milestone payments of up to $555 million.

The company is also advancing its pipeline, including global Phase 3 trials for JR-141 for Hunter syndrome and Phase 3 trials in Japan for JR-142 for growth hormone deficiency. These developments highlight JCR Pharmaceuticals' commitment to expanding its global footprint and developing novel treatments for rare diseases.